Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC
Significant benefit seen for neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.